Skip to main content

beta This is a new site, your feedback will help us to improve it.

Multi-drug resistant organism admission screening

Published on 31 May 2021

We collect, monitor, analyse and interpret information on the uptake of patient screening for multi-drug resistant organisms (MDRO) on admission to hospital. This screening is key to reducing the development and spread of infections in healthcare. Early detection of high-risk patients – using a clinical risk assessment (CRA) based approach – allows early isolation while microbiological samples are tested. This reduces the opportunity for transmission if a patient is colonised or infected.

To ensure that CRA based-screening is as effective as universal screening, a minimum of 90% compliance with application of the CRA is required for methicillin-resistant Staphylococcus aureus (MRSA) Screening and all patients admitted to acute hospitals should be screened by CRA for carbapenemase producing-Enterobacteriaceae (CPE).

Find the two national acute hospital admission MDRO screening policies for:

  • meticillin resistant Staphyloccus aureus (MRSA) screening
  • carbapenemase-producing Enterobacteriaceae (CPE) screening